Caris Life Sciences, Inc.
CAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $7,130,555 | $7,130,555 | $7,134,089 | $502,572 |
| - Cash | $63,950 | $56,402 | $107,191 | $53,547 |
| + Debt | $424,259 | $217,274 | $270,872 | $1,745,731 |
| Enterprise Value | $7,490,864 | $7,291,427 | $7,297,770 | $2,194,756 |
| Revenue | $412,260 | $306,128 | $258,485 | $294,013 |
| % Growth | 34.7% | 18.4% | -12.1% | – |
| Gross Profit | $178,782 | $89,310 | $80,022 | $184,157 |
| % Margin | 43.4% | 29.2% | 31% | 62.6% |
| EBITDA | -$182,952 | -$260,804 | -$245,894 | $254,457 |
| % Margin | -44.4% | -85.2% | -95.1% | 86.5% |
| Net Income | -$281,890 | -$341,415 | -$320,827 | $27,733 |
| % Margin | -68.4% | -111.5% | -124.1% | 9.4% |
| EPS Diluted | -2.7 | -1.82 | -1.57 | 1.55 |
| % Growth | -48.4% | -15.9% | -201.3% | – |
| Operating Cash Flow | -$245,199 | -$276,100 | -$285,706 | $277,016 |
| Capital Expenditures | -$8,444 | -$22,319 | -$42,255 | -$219,450 |
| Free Cash Flow | -$253,643 | -$298,419 | -$327,961 | $57,566 |